ABCD (Huadong Hospital, Fudan University)

**ABCD** is a non-unique acronym for multi-agent multiple-myeloma treatment regimens. In the supplied ChiCTR1800019859 context, it denotes co-administration of **bortezomib, cyclophosphamide, liposomal doxorubicin, and dexamethasone** as induction therapy for newly diagnosed multiple myeloma. Bortezomib inhibits the proteasome, cyclophosphamide alkylates DNA, liposomal doxorubicin intercalates DNA and inhibits topoisomerase II, and dexamethasone activates glucocorticoid receptor signaling to induce lymphoid-cell apoptosis. The acronym is ambiguous in public literature: other ABCD regimens have used different components, including arsenic trioxide, bortezomib, ascorbic acid, and dexamethasone; therefore it should not be treated as a universally standardized product name. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980852/))

Other names

ABCD regimenbortezomib + cyclophosphamide + dexamethasone + liposomal doxorubicinbortezomib + cyclophosphamide + liposomal doxorubicin + dexamethasone